Trial Profile
A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer - follow on study to Study N. ARD-0301-004.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2013
Price :
$35
*
At a glance
- Drugs Teverelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ardana plc
- 23 Aug 2011 New trial record